USANA Health Sciences, Inc. announced its financial results for the third quarter of 2025. Net sales increased 7% year-over-year, reaching $214 million, up from $200 million. The company experienced a net loss, however, of $6.5 million, compared to net earnings of $10.6 million in Q3 2024. Adjusted EBITDA was $13.8 million, down from $24.6 million in the same period last year.
By region, Asia Pacific generated the most revenue, with $140 million in net sales, a 15% sequential decrease. The Americas and Europe showed a 12% sequential increase in net sales, totaling $43 million.
The company’s direct-to-consumer business, Hiya, delivered 26% year-to-date sales growth and made significant progress on several integration initiatives during the quarter. This included a transition to a new logistics partner, which the company believes will drive operational efficiency. Hiya is expected to generate double-digit sales growth for 2025, as well as anticipated long-term growth. Overall, Hiya net sales in Q3 were $31 million with 193,400 active subscribers.
“USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025,” said Jim Brown, USANA President and Chief Executive Officer. “We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. We are encouraged by the pickup in sales activity and leader productivity in recent weeks. Our enhanced compensation plan represents a bold and strategic move to modernize our business and better position our Brand Partners, and the company, for long-term success in a competitive landscape.”
The company ended the quarter with $145 million in cash and cash equivalents with no debt. Fiscal 2025 outlook now includes net sales between $920 million and $1 billion with net earnings expected between $29 million and $41 million.
